Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XCUR Exicure, Inc.

Trading 12-19 09:49:29 EST

6.18

+0.09

+1.48%

High6.18	Low6.10	Vol11.92K
Open6.10	D1 Closing6.09	Amplitude1.31%
Mkt Cap39.39M	Tradable Cap14.39M	Total Shares6.37M
T/O73.39K	T/O Rate0.51%	Tradable Shares2.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XCUR","market":"US","secType":"STK","nameCN":"Exicure, Inc.","latestPrice":6.18,"timestamp":1766155637755,"preClose":6.09,"halted":0,"volume":11922,"delay":0,"floatShares":2327862,"shares":6373869,"eps":-1.72336,"marketStatus":"Trading","change":0.09,"latestTime":"12-19 09:49:29 EST","open":6.1,"high":6.18,"low":6.1,"amount":73387.939467,"amplitude":0.013136,"askPrice":6.38,"askSize":100,"bidPrice":6.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.72336,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766178000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":6.09,"preHourTrading":{"tag":"盘前","latestPrice":6.0913,"preClose":6.09,"latestTime":"09:28 EST","volume":3006,"amount":18497.5761096,"timestamp":1766154529072},"postHourTrading":{"tag":"盘后","latestPrice":5.9958,"preClose":6.09,"latestTime":"19:59 EST","volume":4680,"amount":28529.9843,"timestamp":1766105967040},"volumeRatio":1.58759},"requestUrl":"/m/hq/s/XCUR/tweets","defaultTab":"tweets","newsList":[{"id":"2590323126","title":"Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323126","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323126?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:11","pubTimestamp":1765300316,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49285954/crude-oil-down-1-autozone-shares-dip-after-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","BK4139","BK4563","LU1037948897.HKD","TROX","LU1037948541.HKD","LU1571399168.USD","LU1934455194.USD","SLM","LU0345770308.USD","LU1506573853.SGD","LU0234570918.USD","BK4160","LU1032955483.USD","LU1221951129.SGD","LU2517655291.USD","LU2517655374.HKD","AZO","BK4167","LU1934455863.HKD","LU1221951046.USD","LU0345770993.USD","BK4166","LU0965509010.AUD","LU2463526074.USD","LU0965509101.SGD","XCUR","LU0314106906.USD","BK4212","BK4214","SLMDA","LU1934455277.USD","BK4585","LU1196500208.SGD","BK4090","ALEX","LU0053666078.USD","LU0965509283.SGD","PHR","LU0861579265.USD","BK4588","LU2517655028.SGD"],"gpt_icon":1},{"id":"2590323374","title":"Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323374","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323374?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:39","pubTimestamp":1765298340,"startTime":"0","endTime":"0","summary":"Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its burixafor combination in multiple myeloma.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Molecule-Of-Dna-Forming-Inside-The-Test-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Molecule-Of-Dna-Forming-Inside-The-Test-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49284762/exicure-rally-fueled-by-rapid-cell-boosting-results-in-blood-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49284762/exicure-rally-fueled-by-rapid-cell-boosting-results-in-blood-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE00BLSP4239.USD","IE00B1BXHZ80.USD","LU0234572021.USD","IE00BSNM7G36.USD","SG9999002232.USD","LU1280957306.USD","SG9999002224.SGD","LU1057294990.SGD","LU0889566641.SGD","LU0098860793.USD","LU1935042991.SGD","IE00B2B36J28.USD","BK4588","LU1430594728.SGD","IE0002141913.USD","IE0009355771.USD","LU2089984988.USD","IE00B19Z3581.USD","LU0432979614.USD","LU1506573853.SGD","XCUR","IE0034235303.USD","IE00BFTCPJ56.SGD","LU1059921491.USD","LU2468319806.SGD","LU1894683264.USD","IE00BJJMRZ35.SGD","LU0345770993.USD","LU1267930813.SGD","LU1585245621.USD","LU1061106388.HKD","BK4581","LU2129689605.HKD","LU1674673691.USD","BK4007","IE0002270589.USD","IE00B3T34201.USD","LU0289739699.SGD","LU1196500208.SGD","LU2750360641.GBP","LU1066051225.USD","LU0345770308.USD","LU1244550494.USD","SG9999001440.SGD","IE00BKVL7J92.USD","LU0203345920.USD","IE00B4R5TH58.HKD","JNJ","LU1894683348.USD","LU2129689514.USD"],"gpt_icon":0},{"id":"2590613364","title":"Stocks to Watch: Alexander & Baldwin, Exicure, Mama's Creations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590613364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590613364?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:37","pubTimestamp":1765237020,"startTime":"0","endTime":"0","summary":"Alexander & Baldwin is being taken private in a $1.54 billion deal. Shares jumped 37% to $20.70 in after-hours trading Monday.Exicure shared positive results from a Phase 2 trial of its blood cancer treatment. The stock climbed 83% to $9.85 after the bell.Mama's Creations recorded a 50% bump in revenue. Shares rose 18% to $13.16.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4212","BK4139","ALEX","MAMA","BK4160"],"gpt_icon":0},{"id":"2590136159","title":"Exicure Surges on Positive Data for Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590136159","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590136159?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:43","pubTimestamp":1765233780,"startTime":"0","endTime":"0","summary":"Exicure stock surged after the biopharmaceutical company announced positive results from a Phase 2 trial of its blood cancer treatment.The stock more than doubled in after-hours trading Monday to $11.91, after closing at $5.33.The company said 90% of patients with multiple myeloma who were undergoing stem cell treatment and received doses of burixafor, in combination with certain other treatments, achieved the primary endpoint of the study.The treatment was effective even for participants who had previously received daratumumab, a therapy associated with reduced stem cell mobilization, Exicure said.The company added that the burixafor course of treatment demonstrated a good safety profile.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Exicure Surges on Positive Data for Blood Cancer Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2590036636","title":"Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036636","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036636?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229422,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced positive topline results from a completed Phase 2 clinical trial evaluating burixafor  in combination with propranolol and granulocyte colony-stimulating factor  for mobilizing hematopoietic progenitor cells  in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. The data, presented at the 2025 American Society of Hematology  Annual Meeting, showed that approximately 90% of participants achieved the primary endpoint of collecting ≥2 × 10 CD34+ cells/kg within two leukapheresis sessions. The study reported a favorable safety profile and rapid mobilization kinetics, with peak peripheral CD34+ cell levels observed within one hour of burixafor administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4MvDBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","XCUR","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","BK4588","SG9999014039.USD","SG9999014005.SGD","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2584726546","title":"Exicure Inc. Announces Early Redemption of $3.1 Million Convertible Bonds to Simplify Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2584726546","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584726546?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:53","pubTimestamp":1763416403,"startTime":"0","endTime":"0","summary":"Exicure Inc. has announced the early redemption of 4.5 billion KRW  in 2.90% Convertible Bonds originally due in 2028. The bonds, issued by its subsidiary KC Creation Co., Ltd. and held internally by Exicure, were redeemed in full on November 10, 2025. This move is part of Exicure's ongoing efforts to streamline its intercompany financing and secure liquidity for its biotechnology operations. The transaction, funded through internal cash transfers and involving no third-party holders, is not expected to have a material impact on the company's consolidated financial statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7lDcfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2582388654","title":"Exicure Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388654","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388654?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:18","pubTimestamp":1762809483,"startTime":"0","endTime":"0","summary":"Exicure Inc. held its 2025 Annual Meeting of Stockholders on November 6, 2025. During the meeting, stockholders elected two individuals to the board of directors and ratified the selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1vC6ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2581831358","title":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831358?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:11","pubTimestamp":1762549868,"startTime":"0","endTime":"0","summary":"Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operationsOverviewExicure reports Q3 net loss of $2.4 mln, up from $1.1 mln last yearCompany's cash p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2581397898","title":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2581397898","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581397898?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:01","pubTimestamp":1762549318,"startTime":"0","endTime":"0","summary":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48734306/exicure-q3-eps-0-39-up-from-0-57-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exicure Q3 EPS $(0.39) Up From $(0.57) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2581839297","title":"Exicure reports third quarter net loss of $2.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839297","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839297?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:00","pubTimestamp":1762549224,"startTime":"0","endTime":"0","summary":"Exicure Inc. reported a cash and cash equivalents balance of $4.4 million as of September 30, 2025, compared to $12.5 million at the end of 2024. The company recorded a net loss of $2.4 million for the third quarter of 2025, up from a net loss of $1.1 million in the same period last year. Research and development expenses increased to $0.9 million for the quarter, compared to $0 in the previous year, primarily due to the acquisition of GPCR Therapeutics USA Inc. Exicure management stated that existing cash resources are insufficient to fund ongoing operations and that additional financing is needed in the short term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5fhvzQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","IE00BGHQF748.EUR","BK4588","BK4139","LU2095319765.USD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2581839221","title":"Exicure Q3 Operating Income USD -2.391 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839221?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:00","pubTimestamp":1762549201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXB5CA6C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2581392078","title":"Exicure Inc - Cash Not Sufficient to Fund Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581392078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581392078?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:00","pubTimestamp":1762549201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLXB5CA6C:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2581831156","title":"Exicure, Inc. Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831156","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831156?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:00","pubTimestamp":1762549200,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  07, 2025  (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183943/33289/en/Exicure-Inc-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2580219355","title":"Exicure Unveils Positive Phase 2 Burixafor Data for Multiple Myeloma at 2025 ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219355","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219355?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:00","pubTimestamp":1762178441,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be presented as an oral presentation at the 67th American Society of Hematology  Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The study assessed the safety and efficacy of burixafor in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. The presentation will feature additional patient data from the open-label, multicenter trial and will be delivered by Dr. Jack Khouri of Case Western Reserve University on December 8, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLbWDCjk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","XCUR","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2573682679","title":"Exicure Highlights Recent Achievements and Near-Term Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2573682679","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573682679?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:00","pubTimestamp":1759748400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA97RBB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2571350528","title":"Exicure Inc. Files Initial Statement of Beneficial Ownership for Director Sangjin Yeo","url":"https://stock-news.laohu8.com/highlight/detail?id=2571350528","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571350528?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:11","pubTimestamp":1759176661,"startTime":"0","endTime":"0","summary":"Exicure Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Sangjin Yeo as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL8qvhqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2566643867","title":"Exicure Inc. Appoints Sangjn Yeo and Aejin Hwang to Board Amid Departure of Four Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2566643867","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566643867?lang=en_us&edition=fundamental","pubTime":"2025-09-10 04:20","pubTimestamp":1757449212,"startTime":"0","endTime":"0","summary":"Exicure Inc. announced changes to its Board of Directors on September 8, 2025. Sangjn Yeo and Aejin Hwang have been appointed as Class II directors, with Mr. Yeo also serving as Chairman of the audit committee. Their terms will last until the 2025 annual meeting of stockholders or until successors are appointed. Concurrently, board members Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang have resigned, leaving four vacancies on the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 09, 2025, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL8dmxy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2558574789","title":"Exicure Q2 net loss widens, exploring strategic alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2558574789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558574789?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:11","pubTimestamp":1754683905,"startTime":"0","endTime":"0","summary":"Exicure Q2 net loss widens, exploring strategic alternativesOverviewExicure Q2 net loss widens to $2.6 mln from $0.6 mln yr agoCompany's cash position declines to $7.9 mln from $12.5 mln end of 2024Ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX503A5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2558744835","title":"Exicure Q2 EPS $(0.41) Down From $(0.35) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2558744835","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558744835?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:02","pubTimestamp":1754683336,"startTime":"0","endTime":"0","summary":"Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.41) per share. This is a 17.14 percent decrease over losses of $(0.35) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47013702/exicure-q2-eps-0-41-down-from-0-35-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Exicure Q2 EPS $(0.41) Down From $(0.35) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR"],"gpt_icon":0},{"id":"2558657417","title":"Exicure Inc. Reports Q2 2025 Results: Net Loss Widens to $2.6M Amid Increased R&D and G&A Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2558657417","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558657417?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:01","pubTimestamp":1754683282,"startTime":"0","endTime":"0","summary":"Exicure, Inc.  released its financial results for the second quarter of 2025, reporting a net loss of $2.6 million, an increase from the $0.6 million net loss reported in the same quarter of 2024. This $2 million increase in net loss was primarily attributed to the heightened operating expenses following the acquisition of GPCR Therapeutics USA Inc. . The company's cash and cash equivalents stood at $7.9 million as of June 30, 2025, down from $12.5 million at the end of 2024. Research and development expenses for the quarter were $0.9 million, compared to $0 in the corresponding quarter of the previous year, due to costs associated with GPCR USA's research efforts. General and administrative expenses rose to $1.5 million from $1.2 million, reflecting additional costs related to the acquisition and increased professional services. Exicure also reported a $60,000 loss from the sale of GPCR USA's fixed assets and a $159,000 loss from changes in the fair value of its contingent liability. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL4FhN7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exicuretx.com","stockEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.6331},{"period":"3month","weight":0.5859},{"period":"6month","weight":-0.1847},{"period":"1year","weight":-0.6532},{"period":"ytd","weight":-0.5545}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.021962},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034743},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.055937},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.002351},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.024787},{"month":6,"riseRate":0.25,"avgChangeRate":-0.042251},{"month":7,"riseRate":0.25,"avgChangeRate":-0.052633},{"month":8,"riseRate":0.25,"avgChangeRate":-0.062697},{"month":9,"riseRate":0.25,"avgChangeRate":-0.030428},{"month":10,"riseRate":0.25,"avgChangeRate":-0.064735},{"month":11,"riseRate":0.5,"avgChangeRate":0.997962},{"month":12,"riseRate":0.5,"avgChangeRate":-0.052012}],"exchange":"NASDAQ","name":"Exicure, Inc.","nameEN":"Exicure, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exicure, Inc.,XCUR,Exicure, Inc.股票,Exicure, Inc.股票老虎,Exicure, Inc.股票老虎国际,Exicure, Inc.行情,Exicure, Inc.股票行情,Exicure, Inc.股价,Exicure, Inc.股市,Exicure, Inc.股票价格,Exicure, Inc.股票交易,Exicure, Inc.股票购买,Exicure, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}